文献速递肿瘤 PET/CT核素与放射性配体治疗骨显像与常规 SPECT

骨病灶至关重要:Ga-68 PSMA PET/CT体积参数预测接受[¹⁷⁷Lu]Lu-PSMA-617治疗的骨优势型mCRPC患者的PSA-PFS和OS

Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-29

回顾性纳入56例骨优势型mCRPC患者,在[¹⁷⁷Lu]Lu-PSMA治疗两周期前后行[⁶⁸Ga]Ga-PSMA PET/CT,采用SUV≥3固定阈值提取SUVmean、PSMA-TV和TL-PSMA。中期新病灶及PSMA-TV(Bone)降幅≤10.7%为PSA-PFS独立预测因子,中期PSMA-TV(Bone)>310.3 mL与OS独立相关。

要点

  • 中期PSMA PET/CT出现新病灶及PSMA-TV(Bone)降幅≤10.7%为PSA-PFS缩短的独立预测因子。
  • 中期PSMA-TV(Bone)>310.3 mL在全队列及无早期PSA进展亚组中均为OS独立预后因子。
  • 基线SUVmean与PSA-PFS相关,但与OS无显著关联。

核心结论

  • 在骨优势型mCRPC患者中,ΔPSMA-TV(Bone)≤10.7%和新病灶出现是PSA-PFS的独立预测因子,中期骨肿瘤体积与OS显著相关。
  • 作者认为骨特异性体积参数具有临床相关性,可能作为全身肿瘤评估的潜在替代,提供更实用、更有针对性的预后信息。

研究设计与样本

  • 回顾性研究,纳入56例接受[¹⁷⁷Lu]Lu-PSMA-617治疗的骨优势型mCRPC患者。
  • 患者在[¹⁷⁷Lu]Lu-PSMA治疗两周期前后行[⁶⁸Ga]Ga-PSMA PET/CT显像。
  • 采用SUV≥3固定阈值提取SUVmean、PSMA肿瘤体积(PSMA-TV)和PSMA病灶总活性(TL-PSMA),Δ值为基线与中期扫描间相对变化。
  • 采用Cox回归和Kaplan-Meier生存分析评估与PSA-PFS和OS的关联。

主要发现

  • 中期PSMA PET/CT出现新病灶是PSA-PFS缩短的独立预测因子(p=0.022)。
  • PSMA-TV(Bone)降幅≤10.7%是PSA-PFS缩短的独立预测因子(p=0.043)。
  • 中期PSMA-TV(Bone)>310.3 mL在全队列中为OS的独立预后因子(p<0.001)。
  • 中期PSMA-TV(Bone)>310.3 mL在无早期PSA进展亚组中亦为OS独立预后因子(p=0.002)。
  • 基线SUVmean与PSA-PFS相关,但与OS无显著关联。

关键数值与推荐

  • PSMA PET/CT定量参数提取采用SUV≥3固定阈值。
  • PSMA-TV(Bone)降幅≤10.7%为PSA-PFS缩短的独立预测因子(p=0.043)。
  • 中期PSMA-TV(Bone)>310.3 mL为OS独立预后因子(全队列p<0.001;无早期PSA进展亚组p=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study aimed to evaluate the prognostic value of baseline, interim, and change-based (Δ) volumetric parameters derived from PSMA PET/CT imaging in predicting PSA progression-free survival (PSA-PFS) and overall survival (OS) in bone-dominant metastatic castration-resistant prostate cancer (mCRPC) patients treated with [¹⁷⁷Lu]Lu-PSMA-617. METHODS: This retrospective study included 56 bone-dominant mCRPC patients who underwent [⁶⁸Ga]Ga-PSMA PET/CT imaging before and after two cycles of [¹⁷⁷Lu]Lu-PSMA therapy. Quantitative parameters, including SUVmean, PSMA tumor volume (PSMA-TV), and total lesion PSMA activity (TL-PSMA), were extracted using a fixed threshold of SUV ≥ 3. Δ values were calculated as the relative change between baseline and interim scans. Associations with PSA-PFS and OS were analyzed using Cox regression and Kaplan-Meier survival analyses. RESULTS: The presence of new lesions on interim PSMA PET/CT and a reduction of PSMA-TV(Bone) ≤ 10.7% were identified as independent predictors of shorter PSA-PFS (p = 0.022 and p = 0.043, respectively). For OS, an interim PSMA-TV(Bone) > 310.3 mL remained an independent prognostic factor both in the entire cohort (p < 0.001) and in the subgroup without early PSA progression (p = 0.002). While baseline SUVmean values were associated with PSA-PFS, no significant association with OS was observed. CONCLUSION: In bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA, ΔPSMA-TV(Bone) ≤ 10.7% and the presence of new lesions were independent predictors of PSA-PFS, while interim bone tumor volume was significantly associated with OS. These findings highlight the clinical relevance of bone-specific volumetric parameters, which may serve as a potential alternative to whole-body tumor assessments by providing more practical and targeted prognostic insights in this patient population.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kartal MO, Kartal AS, Coşkun N, et al. Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2025. PMID: 41021003. doi:10.1007/s00259-025-07556-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。